Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (1695)	2/1/1999 7:05:00 PM
From: Ed Ajootian	Read Replies (1) \| Respond to of 10280

RESEARCH ALERT-Sepracor cut to attractive CHICAGO, Feb 1 (Reuters) - Vector Securities International Inc.'s analyst Peter Drake said Monday he has lowered his rating on pharmaceutical company Sepracor Inc. to attractive from buy, citing valuation. -- Sepracor shares have appreciated 30 percent year-to-date and 220 percent over the past 12 months. -- Drake continues to believe in the company's fundamental strength and in the depth of its pipeline. -- Sees approval of its asthma medicine, Xopenex, in the second quarter and said the company should enter into additional partnerships this year. The company should remain a core biotechnology holding, but at current price levels the analyst recommended that investors be more cautious and purchase on weakness. Shares of Sepracor were up 1/8 at 114-7/8 in afternoon trade. ******************************************************************************* Wow, now we're into 2nd qtr. for Xopenex approval. This is getting rediculous. Hopefully Peter Drake does not plan to participate in any more SEPR conference calls --- I bet SEPR will give him the "Maris Treatment"!